ICS-formoterol reliever therapy stepwise treatment algorithm for adult asthma

Richard Beasley 1,2, Irene Braithwaite 1,2, Alex Semprini 1,2, Ciléin Kearns 1,2, Mark Weatherall 2,3, Tim W. Harrison 4, Alberto Papi 5 and Ian D. Pavord 6

Affiliations: 1Medical Research Institute of New Zealand, Wellington, New Zealand. 2Capital and Coast District Health Board, Wellington, New Zealand. 3University of Otago Wellington, Wellington, New Zealand. 4Nottingham NIHR Biomedical Research Centre, University of Nottingham, Nottingham, UK. 5Respiratory Medicine Unit, Dept of Medical Sciences, Università di Ferrara, Ferrara, Italy. 6Oxford Respiratory NIHR BRC, Nuffield Dept of Medicine, University of Oxford, Oxford, UK.

Correspondence: Richard Beasley, Medical Research Institute of New Zealand, Private Bag 7902, Newtown, Wellington 6242, New Zealand. E-mail: richard.beasley@mrinz.ac.nz


This single-page version can be shared freely online.

A stepwise approach to the pharmacological treatment of asthma is a key feature of current asthma guidelines [1–4]. Through algorithms, treatment intensity is “stepped up” to obtain asthma control and reduce the risk of exacerbations, and “stepped down” after a period of prolonged control and absence of exacerbations. Traditional algorithms advocated short-acting β2-agonist (SABA) reliever therapy for all levels of severity, initially as sole therapy at Step 1, together with maintenance “low dose” inhaled corticosteroids (ICS) at Step 2, with maintenance ICS/long-acting β2-agonist (LABA) at “low”, “moderate” or “high” doses at Steps 3 and 4, and finally with “add-on” therapies at Step 5.